Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

被引:43
|
作者
Norum, J.
Olsen, J. A.
Wist, E. A.
Lonning, P. E.
机构
[1] Univ Hosp N Norway, Dept Oncol, N-9038 Tromso, Norway
[2] Univ Tromso, Inst Clin Med, N-9001 Tromso, Norway
[3] Univ Tromso, Inst Community Med, N-9001 Tromso, Norway
[4] Univ Oslo, Hlth Econ Res Programme, N-0316 Oslo, Norway
[5] Ullevaal Univ Hosp, Dept Oncol, Oslo, Norway
[6] Univ Bergen, Inst Internal Med, Sect Oncol, N-5020 Bergen, Norway
关键词
D O I
10.1080/02841860601096841
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Trastuzumab has shown activity in early breast cancer patients that overexpress HER2. Significant resources have to be allocated to finance this therapy, underlining the need for cost-effectiveness analysis. A model was set up, societal costs were calculated and the discount rate was 3%. Life expectancy data were based on the literature and prolonged according to qualified guess (10% and 20% absolute improvement in overall survival (OS)). The comparator was the FEC100 regimen. The median additional health care cost per patient treated was EURO33597. The yielding cost per life year gained (LYG) was 15 341 with a 20% improved OS and EURO35947 with 10% improved OS. The corresponding net health care cost per quality adjusted life year (QALY) was EURO19176 and EURO44934. Including all resource use the figures were EURO8148 and EURO30290 per LYG. Sensitivity analyses documented survival gain, price of trastuzumab, production gain and discount rate to be the major factors influencing cost-effectiveness ratio. Trastuzumab is indicated cost effective in Norway.
引用
收藏
页码:153 / 164
页数:12
相关论文
共 50 条
  • [31] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    PHARMACOECONOMICS, 2018, 36 (01) : 91 - 103
  • [32] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer
    Lidgren, Mathias
    Wilking, Nils
    Jonsson, Bengt
    Rehnberg, Clas
    ACTA ONCOLOGICA, 2008, 47 (06) : 1018 - 1028
  • [34] Cost-effectiveness of various guidelines for adjuvant systemic therapy in primary breast cancer
    Bolster, M.
    Kievit, W.
    Van der Wilt, G. J.
    Adang, E.
    Bult, P.
    Thunnissen, E.
    Meijer, J.
    Beex, L.
    Tjan-Heijnen, V.
    EJC SUPPLEMENTS, 2004, 2 (03): : 75 - 76
  • [35] A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Kurian, Allison W.
    Newton Thompson, Rebecca
    Gaw, Allison F.
    Arai, Sally
    Ortiz, Rafael
    Garber, Alan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 634 - 641
  • [36] COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ADJUVANT BREAST CANCER IN FRANCE
    Gherardi, A.
    Sellami, R.
    Tehard, B.
    Roze, S.
    VALUE IN HEALTH, 2019, 22 : S459 - S459
  • [37] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [38] Adjuvant trastuzumab treatment in early stage breast cancer: Cost-effectiveness in the Belgian health care setting
    Van Vlaenderen, I
    Canon, J.
    Cocquyt, V
    Jerusalem, G.
    Machiels, J.
    Neven, P.
    Nechelput, M.
    Delabaye, I
    Gyldmark, M.
    Annemans, L.
    VALUE IN HEALTH, 2007, 10 (06) : A336 - A336
  • [39] Cost-effectiveness of adjuvant chemotherapy plus trastuzumab (T) in HER2-positive breast cancer
    Liberato, N. L.
    Marchetti, M.
    Barosi, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI6 - XI6
  • [40] IMPACT OF STRUCTURAL ASSUMPTIONS ON COST-EFFECTIVENESS OUTCOMES: TOWARDS A STANDARDIZED COST-EFFECTIVENESS MODEL FOR ADJUVANT BREAST CANCER THERAPIES
    Frederix, G. W.
    Van Hasselt, J. G.
    Schellens, J. H.
    Hovels, A. M.
    Huitema, A. D.
    Raaijmakers, J. A.
    Severens, J.
    VALUE IN HEALTH, 2012, 15 (07) : A282 - A283